Patient P-01714

Synthetic patientNBL-101 · Day 120 · 55–64 · F · baseline S14Steering view · 3D Open companion preview

Therapy response

Improving

Tolerance

Favorable

GI state

Improving

Inflammatory state

Improving

Nutritional resilience

Stable

Discontinuation risk

47%

Trajectory

Baseline → today → 30-day prediction · hover a day for signals and events

solid = observed · dashed = predicted

Day 0 NBL-101 started — Baseline state S14
Day 31 NP-02 recommended — Dietary Support Protocol NP-02
Day 32 Patient accepted — Started NP-02 in the companion
Day 42 No meaningful change — Dietary Support Protocol NP-02
Day 47 Trajectory diverged from prediction — Observed response fell below the model's expected path.
Day 48 SC-12 recommended — Supportive Compound SC-12
Day 49 Patient accepted — Started SC-12 in the companion
Day 55 GI symptom burden −18% vs expected — Supportive Compound SC-12
Day 57 GI-04 recommended — GI Support Protocol GI-04
Day 58 Patient accepted — Started GI-04 in the companion
Day 61 Tolerance state changed — Unstable → Improving
Day 66 GI symptom burden −40% vs expected — GI Support Protocol GI-04
Day 72 Tolerance state changed — Unstable → Improving

What changed?

Trajectory began diverging from predicted response on Day 47.

Primary contributors, last 14 days

Inflammatory activity-11
GI instability-7
Treatment adherence+5
Toxicity-3

What helped?

Dietary Support Protocol NP-02Day 31
Result: no meaningful change
Supportive Compound SC-12Day 48
Result: symptom burden −18%
GI Support Protocol GI-04Day 57
Result: symptom burden −40%

LIFE OS recommendation

Adherence Support AD-05

30%

probability of meaningful tolerance improvement

284 similar trajectories
20% showed improvement
median effect visible after 5 days

Daily trackers

Molecule settings

The trackers this program marks as important, last 14 days vs the 14 before.

GI burden

Companion

27/100

improving · -5.3 vs previous 14 d

Toxicity

Blood

37.3/100

worsening · +7.9 vs previous 14 d

Sleep quality

Wearable

50/100

improving · +8.4 vs previous 14 d

Energy level

Daily log

5.3/10

stable · +0.1 vs previous 14 d

Stress level

Daily log

5.5/10

stable · +0.1 vs previous 14 d

Steps

Wearable

2,912

improving · +232 vs previous 14 d

Adherence

Companion

57.9 %

stable · -0.2 vs previous 14 d

This trajectory is doing well — what to keep, what to watch

Steering view →

Heading towards restoration · 69 from the failing basin, 18 from restoration.

Good elements to keep

GI Support Protocol GI-04
intervention · steering +68.3
Supportive Compound SC-12
intervention · steering +30.3
Dietary Support Protocol NP-02
intervention · steering +13.4
Butyrate producers intact
hidden · steering +7.5

Main detractors to watch

Poor metabolizer
hidden · steering -12.7
FUT2 non-secretor
hidden · steering -10.6
Enterobacteriaceae elevated
hidden · steering -7.4
IL6 high-expression variant
hidden · steering -7.3
Histamine load
detractor · GI +3.4 next day
Spicy / capsaicin
detractor · GI +2.9 next day

State influencers · digestive

Next-day GI change on high-intake vs low-intake days, last 60 days. Attribution from this patient's own log; sensitivity set by their biology.

Histamine load
+3.4detractor · 95%
Spicy / capsaicin
+2.9detractor · 95%
Insoluble fibre
+2.3detractor · 73%
Alcohol
+2.3detractor · 68%
Dietary fat load
+1.3no signal · 38%
Simple carbohydrates
0no signal · 15%

Biological layers

Which pathways look influenced, and by which layer of this person's biology.

Pathways under pressure

Drug metabolism and exposure ↑40
- DNACYP2D6 poor metabolizer → higher exposure
Mucosal barrier integrity ↓30
- DNAFUT2 non-secretor lowers mucosal fucosylation
Inflammatory signalling ↓25
- DNAIL6 -174 variant raises baseline inflammatory tone
Butyrate / short-chain fatty acid production ↓25
- MicrobiomeF. prausnitzii depleted
Autonomic recovery ↓20
- Wearable2,912 steps/day

DNA

Fictional pharmacogenomic panel

FUT2 rs601338 AA (non-secretor)
Reduced mucosal fucosylation
IL6 -174 G/C
Higher inflammatory tone
CYP2D6 Poor metabolizer
Higher exposure at standard dose

Microbiome

Shannon diversity 3.2 · butyrate capacity 45/100

Akkermansia muciniphilaNormal
Faecalibacterium prausnitziiLow
Bacteroides fragilisNormal
Bifidobacterium longumLow
EnterobacteriaceaeHigh

Wearable, last 14 days

daily evolution fed into the runtime

HRV: 51 ms
Sleep: 6.4 h
Steps: 2,487
Resting HR: 67 bpm

Daily log: GI score 27, nutritional resilience 53, adherence 58.

What this patient sees in NostraAI

The content that steers the trajectory: what to eat, what to do, what to take.

Open companion preview

What to eat

Keep meals regular; three to four moderate portions spaced through the day
Include a cooked vegetable portion with each main meal
Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
Avoid known triggers for now: fried or oily food, dairy, alcohol

What to do

Log the daily check-in; one line is enough
A 15-minute walk after lunch
Keep the sleep window steady
Keep hydration steady: small amounts through the day rather than large volumes at once

What to take

Take the scheduled dose as agreed with your care team
No additional supplements this week
Fictional demo item: continue vitamin D as before

284 biologically similar trajectories

Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.

Patient	Similarity	Baseline	Intervention	Outcome	Response today
P-01804	30%	S19	AD-05	improved	61
P-01377	28%	S11	AD-05	no change	42
P-01483	27%	S14	AD-05	no change	35
P-01541	27%	S09	AD-05	no change	43
P-01679	26%	S12	AD-05	no change	39
P-01689	28%	S13	BR-03	no change	50
P-01371	32%	S06	CR-01	improved	63
P-01430	32%	S05	CR-01	improved	54
P-01442	30%	S13	CR-01	improved	61
P-01696	30%	S20	CR-01	improved	59
P-01708	27%	S07	CR-01	improved	59
P-01388	26%	S17	CR-01	improved	59